Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population.

Katarzyna Michalska Ewa Balcerczak Agnieszka Jeleń Lias Saed Pietrzak Jacek Żebrowska-Nawrocka Marta

Published in: Molecular biology reports (2022)

The A388G polymorphism does not seem to affect the increased risk of the development of multiple myeloma. However, the occurrence of the GG genotype may prolong of patients overall survival in the case of Melphalan-Prednisone therapy.

Keyphrases

multiple myeloma
end stage renal disease
ejection fraction
newly diagnosed
risk assessment
high dose
free survival
prognostic factors
patient reported outcomes
mesenchymal stem cells
low dose